xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

39

ICAR SINONASAL TUMORS

FIGURE I.1 Sample paradigm for sequence of diagnosis, management, and survivorship/surveillance for sinonasal tumor patients based on International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) evidence.

FIGURE I.2 Number of annual PubMed-indexed publications from 1976 to 2022 on sinonasal tumors. The search query used was “sinonasal tumors OR sinonasal malignancy.”

like case–control and cohort designs. This highlights the urgent call for further research and investigations in this underresearched field, especially considering the grow ing interest (Figure I.2). Traditionally, rhinology and head and neck oncology have developed separately, focusing on different primary disease processes, namely, QOL and elec tive treatment versus diseases that cause potential harm and mortality. However, there is an opportunity for these specialties to unite and better serve patients. Multidis ciplinary collaboration, such as tumor boards, has been a cornerstone of oncologic care, and we can similarly learn a great deal from medical and radiation oncolo gists who have set higher standards in the literature. In fact, some of the highest levels of evidence within ICSNT are for conditions that are nonsurgically managed, such

as NPC and lymphoma. The future holds promise with prospective, multi-institutional studies that define consis tent interventions and outcome measures, as well as a deeper understanding of tumor biology and its applica tions in precision medicine. It is anticipated that future versions of this document will identify new research ques tions and eventually accrue enough evidence to formulate new recommendations. INTRODUCTION Sinonasal tumors have traditionally been considered rare among head and neck neoplasms, accounting for fewer than 5% of cases. 10 Due to the potential involvement of II